

- Patients with established athero-thrombotic cardiovascular disease
- Patients with an estimated $\geq 15\%$ 5-year risk of a cardiovascular event

n=1000

Randomisation

Treatment strategy based
on the polypill
n=500

Continued
“usual care”
n=500

Scheduled end of follow-up (average 18
months)